| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:08Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; ANN-LII CHENG; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:07Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C.; Hsu C.; Hsu C.-H.; Hsu W.-L.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:06Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.; Hsu C.-H.; Hour T.-C.; ANN-LII CHENG; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:29Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; ANN-LII CHENG; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:27Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
|
Lin C.-C.; Yang C.-H.; ANN-LII CHENG; Chan W.-K.; Ho N.-N. |
| 臺大學術典藏 |
2021-09-01T01:54:19Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W.; Lin C.-C.; Huang T.-C.; ANN-LII CHENG; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S.; Lin C.-C.; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; Yang J.C.-H.; ANN-LII CHENG; Ghalib M.H.; Chuadhary I.; Goel S. |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:48Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C.; Huang T.-C.; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-31T06:29:26Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H.; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:24Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Huang T.-C.; Lin C.-C.; Wu Y.-C.; Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; ANN-LII CHENG; Tzen K.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T03:33:46Z |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Liao B.-C.; Bai Y.-Y.; Lin C.-C.; SHU-YUNG LIN; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2021-08-31T03:33:45Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
SHU-YUNG LIN; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-31T03:33:45Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Liao B.-C.; Bai Y.-Y.; Lee J.-H.; Lin C.-C.; SHU-YUNG LIN; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2021-08-24T08:23:33Z |
Less severe but prolonged course of acute hepatitis a in Human Immunodeficiency Virus (HIV)-infected patients compared with HIV-uninfected patients during an outbreak: A multicenter observational study
|
Lee Y.-L.; Chen G.-J.; Chen N.-Y.; Liou B.-H.; Wang N.-C.; Lee Y.-T.; Yang C.-J.; YU-SHAN HUANG; Tang H.-J.; Huang S.-S.; Lin Y.-C.; Cheng C.-Y.; Lee C.-H.; Chen T.-C.; Wu T.-S.; Liu C.-E.; Lu P.-L.; Hung C.-C.; Lee Y.-C.; Cheng C.-Y.; Cheng S.-H.; YU-SHAN HUANG; Lee Y.-T.; Lin C.-C.; Lin S.-P.; Hsieh C.-Y.; Wang H.-W.; Ho M.-W.; Liu C.-E.; Lee Y.-L.; Lee Y.-C.; Tang H.-J.; Ku H.-C.; Li C.-W.; Lee N.-Y.; Ko W.-C.; Lu P.-L.; Chen Y.-H.; Lin H.-H.; Huang W.-C.; Lee C.-H.; Che T.-C. |
| 臺大學術典藏 |
2021-08-24T06:05:06Z |
Survival of patients aged over 80 years after Austin-Moore hemiarthroplasty and bipolar hemiarthroplasty for femoral neck fractures
|
Lin C.-C.; Huang S.-C.; Ou Y.-K.; Liu Y.-C.; Tsai C.-M.; Chan H.-H.; CHEN-TI WANG |
| 臺大學術典藏 |
2021-08-24T05:21:53Z |
Evidence of Left Ventricular Systolic Dysfunction Detected by Automated Function Imaging in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
|
Liu Y.-W.; Tsai W.-C.; CHI-TING SU; Lin C.-C.; Chen J.-H. |
| 臺大學術典藏 |
2021-08-24T02:10:13Z |
Losartan reduces ensuing chronic kidney disease and mortality after acute kidney injury
|
Cheng S.-Y.; Chou Y.-H.; Liao F.-L.; Lin C.-C.; Chang F.-C.; Liu C.-H.; TAO-MIN HUANG; Lai C.-F.; Lin Y.-F.; Wu V.-C.; Chu T.-S.; Wu M.-S.; Lin S.-L. |
| 臺大學術典藏 |
2021-08-23T23:47:19Z |
Inflammatory macrophages switch to CCL17-expressing phenotype and promote peritoneal fibrosis
|
YI-TING CHEN; Hsu H.; Lin C.-C.; Pan S.-Y.; Liu S.-Y.; Wu C.-F.; Tsai P.-Z.; Liao C.-T.; Cheng H.-T.; Chiang W.-C.; Chen Y.-M.; Chu T.-S.; Lin S.-L. |
| 臺大學術典藏 |
2021-08-23T03:43:55Z |
Losartan reduces ensuing chronic kidney disease and mortality after acute kidney injury
|
Cheng S.-Y.; Chou Y.-H.; Liao F.-L.; Lin C.-C.; FAN-CHI CHANG; Liu C.-H.; Huang T.-M.; Lai C.-F.; Lin Y.-F.; Wu V.-C.; Chu T.-S.; Wu M.-S.; Lin S.-L. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
BIN-CHI LIAO; Lin C.C.; Shih J.Y.; Yang J.C.H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:42Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
BIN-CHI LIAO; Lee J.-H.; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:42Z |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
BIN-CHI LIAO; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
BIN-CHI LIAO; Lin C.-C.; Lee J.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
BIN-CHI LIAO; Lin C.-C.; Lee J.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
BIN-CHI LIAO; Bai Y.-Y.; Lee J.-H.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:38Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; BIN-CHI LIAO; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:38Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T04:13:48Z |
Association between exposure to perfluoroalkyl substances and metabolic syndrome and related outcomes among older residents living near a Science Park in Taiwan
|
Lin T.-W.; Chen M.-K.; Lin C.-C.; Chen M.-H.; Tsai M.-S.; Chan D.-C.; KUAN-YU HUNG; Chen P.-C. |
| 臺大學術典藏 |
2021-08-18T07:39:09Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
JHE-CYUAN GUO; Huang T.-C.; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-18T07:39:07Z |
Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma
|
Yang P.-C.; JHE-CYUAN GUO; Hsieh M.-S.; Lin C.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-18T07:39:06Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
JHE-CYUAN GUO; Lin C.-C.; Huang T.-C.; Huang P.-M.; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; Cheng J.C.-H.; Yeh K.-H.; Hsu C.-H.; Lee J.-M. |
